# Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

> **NCT05642572** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 66 (estimated)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Capmatinib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Osimertinib
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT05642572
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-05
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642572, "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05642572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*